A detailed history of Kistler Tiffany Companies, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Kistler Tiffany Companies, LLC holds 800 shares of EXEL stock, worth $21,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares
800
Previous 800 -0.0%
Holding current value
$21,040
Previous $15,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Jul 20, 2020

BUY
$16.46 - $27.42 $9,876 - $16,452
600 Added 300.0%
800 $19,000
Q3 2017

Oct 19, 2017

BUY
$23.35 - $29.24 $4,670 - $5,848
200
200 $5,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.46B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Kistler Tiffany Companies, LLC Portfolio

Follow Kistler Tiffany Companies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kistler Tiffany Companies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kistler Tiffany Companies, LLC with notifications on news.